We have some trouble with special characters and displaying monographs. 22.09.2018

ATC code:
J05AE10

Classification:
PSP - Possibly porphyrinogenic

Substance:
Darunavir

Rationale for risk classification:
Darunavir is an inhibitor of CYP3A4. Due to lacking pharmacokinetic data it has not been possible to rule out that darunavir might be an inducer or a mechanism-based inhibitor.

Therapeutic characteristics:
Darunavir, co-administered with low dose ritonavir, is indicated with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection.

Side effects or other pharmacodynamic effetc of relevance to acute porphyria:
Common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are diarrhoea, vomiting, nausea and abdominal pain. Another common side effect is increased alanine aminotransferase.

Metabolism and pharmacokinetics:
Darunavir is a moderate inhibitor of CYP3A4 in vivo (FDA and Isoherrannen 2009). Elimination half-life is 15 hours when given with ritonavir.

References: